Clin2
NCT07545681Possibly a fitNot yet recruiting

Testing a new malaria treatment for uncomplicated P. falciparum

Malaria, Falciparum

Treatments studied

Part of Infections clinical trials.

This study tests a new experimental antimalarial drug (GSK3772701) to see if it can safely and effectively treat uncomplicated malaria caused by P. falciparum parasites. You would receive the study drug by mouth and be monitored closely with blood tests and heart rhythm checks.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
70 people
Ages
18 years to 65 years
Study type
Interventional

Who can take part

  • You have confirmed uncomplicated P. falciparum malaria (fever and specific parasite count in your blood)
  • You are between 18 and 65 years old
  • Your weight is healthy (BMI between 18 and 30)
  • You can swallow oral medication and tolerate it without severe vomiting or diarrhea
  • You are willing to use contraception if you are a woman who could become pregnant, for about 40 days
  • You have not taken antimalarial medications in the past 6 weeks

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07646353Not yet recruiting· Phase 1
Safety study of GSK4425689A in healthy adults

This is an early-stage safety study testing a new experimental drug (GSK4425689A) in healthy volunteers. Researchers want to find safe doses and understand how the body processes this medication.

NCT07670377Recruiting· Phase 1
Drug interaction study of GSK3772701 in healthy adults aged 18-55

This trial tests how a new drug (GSK3772701) interacts with another common drug (midazolam) in healthy volunteers. It aims to see if one affects how the other works in the body and will help determine safe dosing for future studies.

Miami, Florida
NCT07011511Recruiting· Phase 1
Testing a new malaria drug in healthy volunteers

This trial tests a new malaria drug (MMV055), alone or with another drug (MMV371), to see if it is safe and how the body processes it. It is for healthy people who want to help find new malaria treatments.

Nottingham
NCT06881732Not yet recruiting· Phase 1
Testing a new malaria vaccine by mosquito bite

This trial uses a genetically modified malaria parasite given by mosquito bite to safely test a new vaccine approach in healthy volunteers. If you qualify, you'll help researchers understand how the body defends against malaria.

Melbourne, Victoria
NCT06862453Recruiting· Phase 1
Safety of a new malaria vaccine in healthy adults

This study tests a new malaria vaccine in healthy adults. You will receive the vaccine and then be exposed to the malaria parasite in a controlled setting to check if the vaccine protects you.

Tübingen
NCT06958198Recruiting· Phase 1
Testing a new multi-stage malaria vaccine in adults and children

This trial tests a new combination of experimental malaria vaccines to see if they are safe and help protect against malaria. It includes both adults and young children in malaria-affected areas.

Siglé, Boulkiemdé Province

Hear when a new Malaria Falciparum trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.